IL101738A - Pharmaceutical preparations for the improvement of symptoms of dementia in humans containing -N -) - 2,6 dimethylphenyl (- 2) -2 oxo-1 pyrolidinyl (acetamide or its salt - Google Patents

Pharmaceutical preparations for the improvement of symptoms of dementia in humans containing -N -) - 2,6 dimethylphenyl (- 2) -2 oxo-1 pyrolidinyl (acetamide or its salt

Info

Publication number
IL101738A
IL101738A IL10173892A IL10173892A IL101738A IL 101738 A IL101738 A IL 101738A IL 10173892 A IL10173892 A IL 10173892A IL 10173892 A IL10173892 A IL 10173892A IL 101738 A IL101738 A IL 101738A
Authority
IL
Israel
Prior art keywords
dementia
pharmaceutical composition
symptoms
mental
dimethylphenyl
Prior art date
Application number
IL10173892A
Other languages
English (en)
Hebrew (he)
Other versions
IL101738A0 (en
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of IL101738A0 publication Critical patent/IL101738A0/xx
Publication of IL101738A publication Critical patent/IL101738A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL10173892A 1991-05-02 1992-04-30 Pharmaceutical preparations for the improvement of symptoms of dementia in humans containing -N -) - 2,6 dimethylphenyl (- 2) -2 oxo-1 pyrolidinyl (acetamide or its salt IL101738A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22981991 1991-05-02
JP22981891 1991-05-02

Publications (2)

Publication Number Publication Date
IL101738A0 IL101738A0 (en) 1992-12-30
IL101738A true IL101738A (en) 1999-01-26

Family

ID=26529012

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10173892A IL101738A (en) 1991-05-02 1992-04-30 Pharmaceutical preparations for the improvement of symptoms of dementia in humans containing -N -) - 2,6 dimethylphenyl (- 2) -2 oxo-1 pyrolidinyl (acetamide or its salt

Country Status (22)

Country Link
US (1) US5886023A (pt)
EP (1) EP0515866B1 (pt)
KR (1) KR100310590B1 (pt)
AT (1) ATE203402T1 (pt)
AU (2) AU1595492A (pt)
CA (1) CA2067614C (pt)
CZ (1) CZ281170B6 (pt)
DE (1) DE69231955T2 (pt)
DK (1) DK0515866T3 (pt)
ES (1) ES2160097T3 (pt)
GR (1) GR3036970T3 (pt)
HK (1) HK1002153A1 (pt)
HU (1) HU224689B1 (pt)
IE (1) IE921377A1 (pt)
IL (1) IL101738A (pt)
MX (1) MX9202058A (pt)
NO (1) NO312813B1 (pt)
PT (1) PT515866E (pt)
RU (1) RU2070042C1 (pt)
SG (1) SG49650A1 (pt)
SK (1) SK279285B6 (pt)
TW (1) TW199096B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1239437A (zh) * 1996-10-01 1999-12-22 第一制药株式会社 线粒体膜稳定剂
CN1264301A (zh) 1997-07-15 2000-08-23 第一制药株式会社 遗忘症的预防、治疗药
WO2000072844A1 (fr) * 1999-05-31 2000-12-07 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs de la mort neuronale
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6423739B1 (en) 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
JPWO2002053153A1 (ja) * 2000-12-28 2004-04-30 第一製薬株式会社 神経因性疼痛治療及び予防薬
ATE404192T1 (de) * 2001-08-22 2008-08-15 Hamilton Pharmaceuticals Inc Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
CN102227217A (zh) * 2008-10-16 2011-10-26 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
EA037187B1 (ru) * 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
IT1141287B (it) * 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
US4385053A (en) * 1981-03-11 1983-05-24 Barry Reisberg Treatment for human memory impairment associated with aging
JPH0699307B2 (ja) * 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti

Also Published As

Publication number Publication date
KR920021143A (ko) 1992-12-18
NO312813B1 (no) 2002-07-08
IL101738A0 (en) 1992-12-30
SG49650A1 (en) 1998-06-15
CZ281170B6 (cs) 1996-07-17
AU3774595A (en) 1996-03-07
HU224689B1 (hu) 2005-12-28
US5886023A (en) 1999-03-23
CS130692A3 (en) 1992-11-18
DK0515866T3 (da) 2001-09-24
ES2160097T3 (es) 2001-11-01
EP0515866A1 (en) 1992-12-02
KR100310590B1 (ko) 2001-12-28
NO921724D0 (no) 1992-04-30
IE921377A1 (en) 1992-11-04
TW199096B (pt) 1993-02-01
GR3036970T3 (en) 2002-01-31
DE69231955D1 (de) 2001-08-30
MX9202058A (es) 1993-03-01
CA2067614A1 (en) 1992-11-03
SK279285B6 (sk) 1998-09-09
DE69231955T2 (de) 2002-04-04
AU697936B2 (en) 1998-10-22
AU1595492A (en) 1992-11-05
CA2067614C (en) 2002-07-30
HU9201477D0 (en) 1992-07-28
HK1002153A1 (en) 1998-07-31
PT515866E (pt) 2001-11-30
ATE203402T1 (de) 2001-08-15
EP0515866B1 (en) 2001-07-25
HUT62790A (en) 1993-06-28
RU2070042C1 (ru) 1996-12-10
NO921724L (no) 1992-11-03

Similar Documents

Publication Publication Date Title
IL101738A (en) Pharmaceutical preparations for the improvement of symptoms of dementia in humans containing -N -) - 2,6 dimethylphenyl (- 2) -2 oxo-1 pyrolidinyl (acetamide or its salt
Schapira et al. Study on the effects of tablet colour in the treatment of anxiety states
US4663318A (en) Method of treating Alzheimer's disease
IE83506B1 (en) Use of N-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamide for the treatment of dementia
KR20060130649A (ko) 근위축성 측색경화증(ａｌｓ) 또는 ａｌｓ에 기인하는질환의 신규 치료제
CA2294589A1 (en) Composition for controlling mood disorders in healthy individuals
Chadwick et al. Acute intoxication with sodium valproate
KR20070084123A (ko) 양극성 장애 및 관련 증상의 치료
EP0825857B1 (en) Use of gabapentin and its derivatives in the treatment of mania and bipolar disorder
CN1053341C (zh) 还原形式的烟酰胺腺嘌呤二核苷酸或烟酰胺腺嘌呤二核苷酸磷酸或其盐的制药用途
JP3464012B2 (ja) 精神症候治療剤
Bouvet et al. Fatal acetaminophen poisoning with hepatic microvesicular steatosis in a child after repeated administration of therapeutic doses
JP5459934B2 (ja) 神経接続欠陥、例えば精神分裂病及び自閉症の治療においてエポチロン（ｅｐｏｔｈｉｌｏｎｅ）を使用する方法
Absher et al. Cognitive and noncognitive aspects of dementia syndromes: an overview
Homeida et al. Dapsone-induced optic atrophy and motor neuropathy.
EP0600582B1 (en) Treatment for muscular dystrophy
Bowerman et al. Premature deaths in persons with seizure disorders—subtherapeutic levels of anticonvulsant drugs in postmortem blood specimens
ANTON et al. Case report of carbamazepine treatment of organic brain syndrome with psychotic features
JP3388777B2 (ja) アルツハイマー型痴呆改善剤
Chia et al. Parkinson's disease in Taiwan: an analysis of 215 patients
JP3388778B2 (ja) 脳血管性痴呆改善剤
CA2049977A1 (en) Nootropic agent
JP4120713B2 (ja) 多発性硬化症治療剤
Wszolek et al. Seizures after liver transplantation
Bennie et al. Comparison of trazodone and mianserin in depressive illness

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed